Skip to content

Systemic chemotherapy

TL;DR — Intravenous chemotherapy is a platform rather than a stand-alone eye treatment: vincristine–etoposide–carboplatin (VEC/CEV) reduces intraocular tumour and is followed by focal consolidation. It also treats bilateral disease systemically and remains central for high-risk pathology and extraocular disease. Toxicity includes myelosuppression, infection, ototoxicity and therapy-related malignancy concerns; route comparisons must therefore count child-level burden as well as eye salvage. Modern randomized evidence supports shorter adjuvant therapy in a defined postenucleation high-risk population, not automatic shortening in every risk stratum.

Decision-relevant evidence

  • Intravenous chemotherapy was available to 98.8% of 4,064 children in the global cohort, showing that nominal availability alone did not erase mortality inequity (PMID 35839812).

  • A randomized trial of 187 enucleated unilateral high-risk cases found five-year disease-free survival 90.4% with three CEV cycles versus 89.2% with six; difference 1.2% (95% CI −7.5 to 9.8), meeting its 12% noninferiority margin (P = .003), with more adverse events, greater quality-of-life reduction and higher costs in the six-cycle arm (Ye 2024, PMID 39432296; NCT01906814).

  • Raising the carboplatin dose does not buy globe or vision salvage. In a single-blinded randomized trial of 32 eyes in 30 children with group D or E disease, standard versus higher-dose carboplatin (18.6 versus 28 mg/kg under 36 months; 560 versus 840 mg/m² at or above 36 months) gave comparable regression pattern (P = .72), tumour shrinkage (diameter P = .11, height P = .96), subretinal seeds (P = .91) and vitreous seeds (P = .9); globe salvage was 82% versus 67% in group D (P = .58) and 12.5% versus 29% in group E (P = .57), with no excess toxicity in the higher-dose arm (Roy 2023, PMID 37243382). The trial is small, so it excludes a large benefit rather than a small one.

  • Which agents are in the regimen matters more than how much of one of them. In a prospective observational study of 164 eyes in Germany and Austria, two-year event-free eye survival was 72.3% with VEC versus 50.4% with CyVEC (log-rank P < .001) despite the cyclophosphamide-containing arm, while overall eye survival did not differ (82.1% versus 84.8%, P = .77). Advanced ICRB group dominated both endpoints (two-year event-free eye survival 71.3% for A/B/C versus 43.0% for D/E; overall eye survival 93.1% versus 61.5%, both P < .0001) (Grümme 2022, PMID 34606174).

  • Cooperative-group trials define the achievable ceiling by group. In ARET0331, six cycles of vincristine–carboplatin plus local therapy in 21 patients (25 eyes) with group B disease gave two-year event-free survival of 65% — below the design threshold, closing the study early — with two-year cumulative incidence of enucleation 15%, external-beam radiotherapy 10% and additional chemotherapy 10%; every failure was salvaged (Friedman 2017, PMID 28019092). In ARET0231, adding sub-Tenon carboplatin to CEV in group C/D eyes gave a one-year group D failure rate of 52%, better than the 70% historical rate (P = .039) with 80% one-year eye preservation, but at the cost of periorbital fat atrophy in 45% of eyes, and the authors judged the ocular toxicity unacceptable (Jubran 2020, PMID 32589362).

  • Systemic chemotherapy alone leaves seeds behind. Ten eyes enucleated after chemoreduction with no adjuvant focal therapy showed mean regression of 34% in thickness and 24% in basal diameter; enucleation was prompted by subretinal and/or vitreous seed recurrence in 7 eyes and never by main-tumour recurrence, and 2 of 10 eyes still contained mitotically active viable tumour (Demirci 2003, PMID 12912690).

  • Pooled comparison with the arterial route favours IAC only in the middle of the stage range. A meta-analysis of 26 studies and 1,541 eyes found higher overall success with IAC than intravenous chemotherapy (75.7%, 95% CI 65.7–83.6 versus 69.5%, 51.9–82.8; P < 0.001), driven by group D (79.5%, 71.8–85.4 versus 55.1%, 45.6–64.2; P < 0.001) with no significant difference in groups B, C or E, and no difference in recurrence (15.0% versus 15.4%, P = 0.148) or metastasis (2.7% versus 0.6%, P = 0.194). Follow-up was much shorter for IAC (mean 21.7 versus 49.4 months), which is the main reason the metastasis comparison is weak (Chen 2018, PMID 29703164).

  • Prolonged attempts at salvage before enucleation cost survival in advanced eyes. Across 29 Chinese centres, delay from diagnosis to enucleation beyond 3.5 months (group D) or 2 months (group E) reduced disease-specific survival (P = 0.018 and P = 0.017); four or more pre-enucleation cycles in group E eyes worsened survival versus primary enucleation (P = 0.025), and pre-enucleation chemotherapy was followed by more pT3/pT4 pathology in group E (P < 0.001). Post-enucleation chemotherapy improved survival where high-risk pathology was present (Zhao 2020, PMID 32387053).

  • For extraocular disease, VEC produced a four-year survival estimate of 63% (95% CI 0.41–0.79) versus 25% (0.08–0.46) with a more toxic alternating five-drug regimen in a 54-child randomized comparison, with grade 4 neutropenia significantly more common in the five-drug arm (P = 0.002) (Chawla 2016, PMID 27449712).

  • Diffuse infiltrating retinoblastoma is the intraocular presentation where chemotherapy is least often the primary choice: 81% of 132 international cases went to primary enucleation and 19% received systemic chemotherapy first, of whom 6% required later enucleation; five-year survival for cT3 diffuse infiltrating disease was 82% versus 94% for cT3 non-diffuse (P < 0.001) (Tomar 2025, PMID 40738737).

Clinical and research frame

Domain Operational meaning Evidence boundary
Intraocular chemoreduction VEC/CEV plus focal consolidation Eye response; systemic burden
Bilateral disease Treat both eyes during same course Eye-specific local therapy still required
High-risk pathology Adjuvant systemic therapy Prevent systemic relapse
Orbital/metastatic disease Multiagent intensive therapy Life salvage, not eye salvage
Bridge in very young infants Temporary systemic control Center-specific route sequencing

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
39432296 2024 Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. Topic-resolved source (Ye 2024, PMID 39432296)
27449712 2016 Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. Topic-resolved source (Chawla 2016, PMID 27449712)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
33120616 2020 Modern treatment of retinoblastoma: A 2020 review. Topic-resolved source (Ancona-Lezama 2020, PMID 33120616)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
40731848 2025 Update on Retinoblastoma Therapies. Topic-resolved source (Martínez 2025, PMID 40731848)
32206913 2020 [Retinoblastoma]. Topic-resolved source (Bornfeld 2020, PMID 32206913)
16139001 2005 Chemoreduction in the management of retinoblastoma. Topic-resolved source (Shields 2005, PMID 16139001)
39620227 2024 Prospects of anti-GD2 immunotherapy for retinoblastoma. Topic-resolved source (Zhang 2024, PMID 39620227)
40471757 2025 Managing retinoblastoma in 2025. Topic-resolved source (Ramos-Dávila 2025, PMID 40471757)
20224400 2010 Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Topic-resolved source (Shields 2010, PMID 20224400)
40738737 2025 Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study. Topic-resolved source (Tomar 2025, PMID 40738737)
32920208 2021 Adverse Events, Treatment Burden, and Outcomes of Intravenous versus Intra-arterial Chemotherapy for Retinoblastoma. Topic-resolved source (Santapuram 2021, PMID 32920208)
32925294 2020 Chemotherapy for Retinoblastoma: Impact of Intravitreal Chemotherapy. Topic-resolved source (Raval 2020, PMID 32925294)
22995941 2013 Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Topic-resolved source (Shields 2013, PMID 22995941)
27218786 2016 Therapeutic Options for Retinoblastoma. Topic-resolved source (Mendoza 2016, PMID 27218786)
27800245 2015 Chemotherapy in Retinoblastoma: Current Approaches. Topic-resolved source (Yanık 2015, PMID 27800245)
22450222 2012 Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned? Topic-resolved source (Shields 2012, PMID 22450222)
10623718 2000 Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. Topic-resolved source (Shields 2000, PMID 10623718)
38609685 2024 Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Meel 2024, PMID 38609685)
38431272 2024 Management of retinoblastoma: are we there yet? Topic-resolved source (Raval 2024, PMID 38431272)
36727336 2023 Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma. Topic-resolved source (Kumari 2023, PMID 36727336)
42463304 2026 Global retinoblastoma service availability in 2024 and equity trends since 2017. Topic-resolved source (Global 2026, PMID 42463304)
38641204 2024 Update on chemotherapy modalities for retinoblastoma: Progress and challenges. Topic-resolved source (Kritfuangfoo 2024, PMID 38641204)
12912690 2003 Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Topic-resolved source (Demirci 2003, PMID 12912690)
23024125 2013 Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Topic-resolved source (Schaiquevich 2013, PMID 23024125)
35820112 2022 Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Topic-resolved source (Dunkel 2022, PMID 35820112)
37817345 2024 A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Topic-resolved source (Chintagumpala 2024, PMID 37817345)
32589362 2020 A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). Topic-resolved source (Jubran 2020, PMID 32589362)
28019092 2017 Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Topic-resolved source (Friedman 2017, PMID 28019092)
37536351 2023 Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. Topic-resolved source (Wen 2023, PMID 37536351)
39528689 2024 Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial. Topic-resolved source (Zeng 2024, PMID 39528689)
29703164 2018 Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. Topic-resolved source (Chen 2018, PMID 29703164)
40541288 2025 Intra-arterial chemotherapy for retinoblastoma: a performance analysis. Topic-resolved source (Weinberger 2025, PMID 40541288)
40061040 2023 Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastoma. Topic-resolved source (Diarra 2023, PMID 40061040)
32387053 2020 Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma. Topic-resolved source (Zhao 2020, PMID 32387053)
34606174 2022 Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. Topic-resolved source (Grümme 2022, PMID 34606174)
15136321 2004 Practical approach to management of retinoblastoma. Topic-resolved source (Shields 2004, PMID 15136321)
37243382 2023 A single-blinded, randomized controlled trial of standard versus higher dose carboplatin-based intravenous chemotherapy for group D and E retinoblastoma. Added by audit 2026-09-01 (Roy 2023, PMID 37243382)

Source chronology

Era marker PMID What the record contributes
2000 10623718 Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. (Shields 2000, PMID 10623718)
2003 12912690 Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. (Demirci 2003, PMID 12912690)
2004 15136321 Practical approach to management of retinoblastoma. (Shields 2004, PMID 15136321)
2005 16139001 Chemoreduction in the management of retinoblastoma. (Shields 2005, PMID 16139001)
2010 20224400 Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. (Shields 2010, PMID 20224400)
2012 22450222 Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned? (Shields 2012, PMID 22450222)
2013 22995941 Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. (Shields 2013, PMID 22995941)
2013 23024125 Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. (Schaiquevich 2013, PMID 23024125)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2015 27800245 Chemotherapy in Retinoblastoma: Current Approaches. (Yanık 2015, PMID 27800245)
2016 27218786 Therapeutic Options for Retinoblastoma. (Mendoza 2016, PMID 27218786)
2016 27449712 Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. (Chawla 2016, PMID 27449712)
2017 28019092 Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. (Friedman 2017, PMID 28019092)
2017 28620731 Retinoblastoma. (Rao 2017, PMID 28620731)
2018 29703164 Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. (Chen 2018, PMID 29703164)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which high-risk pathology subsets require three, six or zero adjuvant cycles? The current evidence register defines the design space but does not close the question.

  • What late toxicity differs between intravenous and intra-arterial first-line strategies? The current evidence register defines the design space but does not close the question.

  • How should bilateral child-level outcomes be compared with eye-level salvage? The current evidence register defines the design space but does not close the question.

References

  1. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  2. Ye H, et al. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. JAMA. 2024;332:1634-1641. PMID 39432296
  3. Chawla B, et al. Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. Ophthalmology. 2016;123:1933-9. PMID 27449712
  4. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  5. Ancona-Lezama D, et al. Modern treatment of retinoblastoma: A 2020 review. Indian journal of ophthalmology. 2020;68:2356-2365. PMID 33120616
  6. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  7. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  8. Martínez Arce CA, et al. Update on Retinoblastoma Therapies. Medicina (Kaunas, Lithuania). 2025;61. PMID 40731848
  9. Bornfeld N, et al. [Retinoblastoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2020;117:389-402. PMID 32206913
  10. Shields JA, et al. Chemoreduction in the management of retinoblastoma. American journal of ophthalmology. 2005;140:505-6. PMID 16139001
  11. Zhang X, et al. Prospects of anti-GD2 immunotherapy for retinoblastoma. Frontiers in immunology. 2024;15:1499700. PMID 39620227
  12. Ramos-Dávila EM, et al. Managing retinoblastoma in 2025. Current opinion in ophthalmology. 2025;36:414-426. PMID 40471757
  13. Shields CL, et al. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Current opinion in ophthalmology. 2010;21:203-12. PMID 20224400
  14. Tomar AS, et al. Diffuse infiltrating retinoblastoma: a multicentre, international, data-sharing study. The British journal of ophthalmology. 2025;109:1409-1416. PMID 40738737
  15. Santapuram PR, et al. Adverse Events, Treatment Burden, and Outcomes of Intravenous versus Intra-arterial Chemotherapy for Retinoblastoma. Ophthalmology. Retina. 2021;5:309-312. PMID 32920208
  16. Raval V, et al. Chemotherapy for Retinoblastoma: Impact of Intravitreal Chemotherapy. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2020;10:200-202. PMID 32925294
  17. Shields CL, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (London, England). 2013;27:253-64. PMID 22995941
  18. Mendoza PR, et al. Therapeutic Options for Retinoblastoma. Cancer control : journal of the Moffitt Cancer Center. 2016;23:99-109. PMID 27218786
  19. Yanık Ö, et al. Chemotherapy in Retinoblastoma: Current Approaches. Turkish journal of ophthalmology. 2015;45:259-267. PMID 27800245
  20. Shields CL, et al. Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned? Current opinion in ophthalmology. 2012;23:202-9. PMID 22450222
  21. Shields CL, et al. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18:236-7. PMID 10623718
  22. Meel R, et al. Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1166-1176. PMID 38609685
  23. Raval V, et al. Management of retinoblastoma: are we there yet? Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2024;59:376-379. PMID 38431272
  24. Kumari N, et al. Intra-arterial chemotherapy in refractory and advanced intraocular retinoblastoma. Indian journal of ophthalmology. 2023;71:436-443. PMID 36727336
  25. Global Retinoblastoma Study Group. Global retinoblastoma service availability in 2024 and equity trends since 2017. The British journal of ophthalmology. 2026. PMID 42463304
  26. Kritfuangfoo T, et al. Update on chemotherapy modalities for retinoblastoma: Progress and challenges. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100061. PMID 38641204
  27. Demirci H, et al. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Archives of ophthalmology (Chicago, Ill. : 1960). 2003;121:1125-31. PMID 12912690
  28. Schaiquevich P, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatric blood & cancer. 2013;60:766-70. PMID 23024125
  29. Dunkel IJ, et al. Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:3839-3847. PMID 35820112
  30. Chintagumpala M, et al. A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Pediatric blood & cancer. 2024;71:e30718. PMID 37817345
  31. Jubran RF, et al. A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). Pediatric blood & cancer. 2020;67:e28502. PMID 32589362
  32. Friedman DL, et al. Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Pediatric blood & cancer. 2017;64. PMID 28019092
  33. Wen X, et al. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. The Lancet. Child & adolescent health. 2023;7:613-620. PMID 37536351
  34. Zeng C, et al. Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial. Scientific reports. 2024;14:27613. PMID 39528689
  35. Chen Q, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC cancer. 2018;18:486. PMID 29703164
  36. Weinberger Y, et al. Intra-arterial chemotherapy for retinoblastoma: a performance analysis. The British journal of ophthalmology. 2025;109:1298-1305. PMID 40541288
  37. Diarra Y, et al. Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastoma. EJC paediatric oncology. 2023;1:None. PMID 40061040
  38. Zhao J, et al. Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma. Ophthalmology. Retina. 2020;4:630-639. PMID 32387053
  39. Grümme L, et al. Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma. Pediatric blood & cancer. 2022;69:e29362. PMID 34606174
  40. Shields CL, et al. Practical approach to management of retinoblastoma. Archives of ophthalmology (Chicago, Ill. : 1960). 2004;122:729-35. PMID 15136321
  41. Roy PS, et al. A single-blinded, randomized controlled trial of standard versus higher dose carboplatin-based intravenous chemotherapy for group D and E retinoblastoma. Pediatric blood & cancer. 2023;70:e30444. PMID 37243382